A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice.

Trial Profile

A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Apr 2016 Status changed from active, no longer recruiting to discontinued as FAS 500 mg has launched in 2015. and the use mothod of 250mg per month in clinical practice is off-label as reported by ClinicalTrials.gov.
    • 16 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 25 Feb 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Jan 2014 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top